Mapi Pharma

Formulations That Meet Unmet Patient Needs

Focused on long acting
depot injections

Developing Finished Dosage Forms and a Portfolio of APIs

Fully integrated GMP
manufacturing facilities

Pipeline of Multiple Late Stage Products

In Phase III for RMS and Phase II for
PPMS for treating MS

We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.

Focus

Our main focus is on developing long acting depot injectable drugs.

Programs

Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica^®) for pain.

Latest News

Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries

October 7, 2020

Facility in the Jerusalem Har-Hotzim technology park is built at the highest GMP standards; capability to provide reliable supply of COVID-19 vaccines, if approved NESS ZIONA, Israel – Oct. 7, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage...

Jingxin 30th Anniversary Greeting from Mapi Pharma

September 30, 2020

NESS ZIONA, Israel, September 30, 2020 -- Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today greets its partner, Zhejiang Jingxin Pharmaceutical Co Ltd. To our friends and partners at Jingxin Pharma, On...